Fresenius Kabi: No Launches From US Melrose Park Facility In 2021
Market Fears Warning Letter At Key US Facility
Fresenius Kabi saw a sales and earnings slump in its North America business in the final quarter of last year, which dragged heavily on the firm’s full-year operations. Management have conceded that one of those factors, manufacturing issues at its Melrose Park facility, will blow into 2021, with no product approvals or launches anticipated from the site.
